Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
15.10
+0.55 (3.78%)
May 18, 2026, 4:00 PM EDT - Market closed
Caris Life Sciences Revenue
Caris Life Sciences had revenue of $216.17M in the quarter ending March 31, 2026, with 78.78% growth. This brings the company's revenue in the last twelve months to $907.29M, up 100.51% year-over-year. In the year 2025, Caris Life Sciences had annual revenue of $812.03M with 96.97% growth.
Revenue (ttm)
$907.29M
Revenue Growth
+100.51%
P/S Ratio
4.70
Revenue / Employee
$491,491
Employees
1,846
Market Cap
4.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 812.03M | 399.77M | 96.97% |
| Dec 31, 2024 | 412.26M | 106.13M | 34.67% |
| Dec 31, 2023 | 306.13M | 47.64M | 18.43% |
| Dec 31, 2022 | 258.49M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCAI News
- 6 days ago - Caris Life Sciences Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 7 days ago - Caris Life Sciences announces publication of study on measuring TMB using WES - TheFly
- 10 days ago - Caris Life Sciences submits application to NYSDOH for Caris Assure testing - TheFly
- 10 days ago - Caris Life Sciences price target lowered to $22 from $28 at Baird - TheFly
- 10 days ago - Caris Life Sciences price target lowered to $32 from $38 at BTIG - TheFly
- 10 days ago - Caris Life Sciences price target lowered to $30 from $35 at JPMorgan - TheFly
- 10 days ago - Caris Life Sciences price target lowered to $28 from $35 at Citi - TheFly
- 11 days ago - Caris Life Sciences reports Q1 EPS 0c, consensus (2c) - TheFly